What are the Overall Strategies for Post-Thrombolytic Care That Include Use of Angioplasty?
The approach to the treatment of patients with acute myocardial infarction has changed markedly over the past several years. These changes have centered on the initial management of patients with evolving myocardial infarction. The major focus of treatment now includes widespread use of thrombolytic agents. This new approach has important implications for overall strategies in the management of patients with myocardial infarction. The purpose of this paper is to address strategies for post-thrombolytic care that use mechanical recanalization in an attempt to enhance the outcome of thrombolysis alone.
KeywordsAcute Myocardial Infarction Thrombolytic Therapy Thrombolytic Agent Anisoylated Plasminogen Streptokinase Activator Complex Recurrent Ischemic Event
Unable to display preview. Download preview PDF.
- 3.AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial (In press).Google Scholar
- 8.Gruppo Italiano per lo Studio della Streptochinasi Nell’Infarto Miocardica (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI study. Lancet 1987;2:871–874.Google Scholar
- 12.Topol EJ, et al., and the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581–588.PubMedCrossRefGoogle Scholar
- 18.Holland K, et al. Emergency coronary angioplasty therapy for elderly patients with acute myocardial infarction: cautionary results (abstr). J Am Coll Cardiol 1987;9:232A.Google Scholar
- 19.TIMI Operations Committee. Announcement of protocol change in Thrombolysis in Myocardial Infarction Trial (Letter to Editor). J Am Coll Cardiol 1987;9:467.Google Scholar
- 23.Lee CD, et al. The activation of human coagulation factor V by plasmin (abstr). Blood 1987;70:389a.Google Scholar
- 24.Sobel M, et al. Platelet activation enhances heparin binding (abstr). Blood 1987;70:361a.Google Scholar
- 26.Shebuski RJ. Effect of thromboxane A2 (TXA) receptor antagonist (TRA) alone and in combination with a thromboxane synthetase inhibitor (TSI) on cyclic flow reduction (CFRs) in stenosed coronary arteries (abstr). Circulation 1987;76:IV–101.Google Scholar